New study advances cancer precision therapies by identifying patients who benefit from Bexmarilimab treatment Researchers at the University of Turku, Finland, have taken a step towards more personalised and effective cancer treatments.

Antibody drug #Bexmarilimab, developed in Finland, has shown promising results in several types of solid tumours. A new study by Associate Professor Maija Hollmén adds important insights into how Bexmarilimab can be used most effectively in the future.
@inflames-flagship.bsky.social
#immunology

Hematology Weekly News – April 21st 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week 🧬 This Week in Hematology: Game-Changing Approvals, Breakthrough Trials & Promising Therapies […] The post Hematology Weekly News – April 21st 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – April 21st 2025 #News #bexmarilimab #Blenrep #CARTtherapy Comment below!

Hematology Weekly News – April 21st 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week 🧬 This Week in Hematology: Game-Changing Approvals, Breakthrough Trials & Promising Therapies […] The post Hematology Weekly News – April 21st 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – April 21st 2025 #News #bexmarilimab #Blenrep #CARTtherapy Comment below!

Faron Pharmaceuticals Secures Regulatory Milestones for Bexmarilimab in the UK Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical innovator focused on developing novel immunotherapies to tackle cancers, has made significant strides with its leading candidate, bexmari...

www.linkedin.com/pulse/faron-...

Faron Pharmaceuticals Secures Regulatory Milestones for Bexmarilimab in the UK

kstrategyand.com/pharma-news

#FaronPharmaceuticals #Bexmarilimab #ILAP #MHRA #HealthcareInnovation #Humanteconomy #Humantech #KStrategyand